Precede Biosciences
PrivateLast Round
Series B
Jan 12, 2026
Total Funding Raised
$140.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Precede Biosciences operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series B round in January 2026.
Precede Biosciences is a biotechnology company that offers a liquid biopsy platform for in-depth analysis of disease-related biology through a simple blood test.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Data as a Service, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Precede Biosciences Comparables
Compare Precede Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Adela | 87% | |
| Aqtual | 85% | |
| Tagomics Ltd. | 82% |
For institutional investors. Book with your work email.
Precede Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 12, 2026 | ||||
| Debt | Jan 12, 2026 | ||||
| Series A | Oct 5, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Precede Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Binney Street Capital | Seed, Series A, Series B |
| Osage University Partners | Series A, Series B |
| 5AM Ventures | Seed, Series B, Series A |
| Alexandria Venture Investments | Series B |
| Mirae Asset Capital Life Science | Series B |
| Mirae Asset Capital | Series B |
| Lilly Asia Ventures | Series B, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 21, 2026
Launched Precede Bio Insight, an epigenomic liquid biopsy platform.
- Apr 17, 2026
Presented new data at the AACR 2026 Annual Meeting.
For institutional investors. Book with your work email.
Precede Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Precede Biosciences's valuation, stock price, and market status.
Is Precede Biosciences a public or private company?
Precede Biosciences is a private company.
What is the current stock price of Precede Biosciences?
Precede Biosciences is a private company, so its shares have no public market price. Caplight tracks Precede Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Precede Biosciences worth (valuation)?
Valuation information for Precede Biosciences is not publicly available.
Can I buy Precede Biosciences stock?
Precede Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Precede Biosciences's last funding round?
Precede Biosciences's most recent funding round was Series B on January 12, 2026.
Who are the main investors in Precede Biosciences?
Key investors in Precede Biosciences include 5AM Ventures, Lilly Asia Ventures, Lilly Asia Ventures.
Will Precede Biosciences IPO soon?
No public IPO plans have been announced for Precede Biosciences.
How can I track Precede Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Precede Biosciences's shares on secondary markets.